Balchem Corp. 10-K Summary: Fiscal Year Ended December 31, 2001
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2001. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for food, feed, and medical sterilization industries. Effective June 1, 2001, the Company acquired assets from DCV, Inc. and DuCoa L.P., expanding operations into three segments: Specialty Products, Encapsulated/Nutritional Products, and Unencapsulated Feed Supplements. The acquisition included a manufacturing facility in Verona, Missouri.
Key Financial Metrics
| Metric (in thousands) | 2001 | 2000 |
|---|---|---|
| Net Sales | $46,142 | $33,198 |
| Gross Profit | $17,926 | $14,041 |
| Gross Margin | 39% | 42% |
| Operating Earnings | $8,155 | $5,938 |
| Net Earnings | $5,110 | $3,729 |
| Diluted EPS | $1.05 | $0.78 |
| Cash Flow from Operations | $3,222 | $5,953 |
| Total Assets | $44,477 | $23,222 |
| Long-Term Debt | $11,323 | $0 |
| Total Stockholders' Equity | $25,332 | $19,580 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 39% to $46.1 million, driven primarily by the June 2001 acquisition which added $6.7 million in feed supplement sales and boosted the Encapsulated/Nutritional segment by 40%.
- Margin Compression: Gross margin declined from 42% to 39% due to the inclusion of lower-margin feed products from the new segment, partially offset by favorable product mix in the Specialty Products segment.
- Debt Structure: The Company incurred $13.5 million in long-term debt to finance the acquisition, resulting in interest expense rising from $48,000 to $387,000.
- Operating Expenses: Increased 21% to $9.8 million, primarily due to added personnel for sales, marketing, and R&D to support the expanded business.
- One-Time Income: Other income included $491,000 from the settlement of a class-action antitrust claim related to vitamin products.
Outlook, Risks, and Management Commentary
- Capital Projects: Capital expenditures were $1.95 million in 2001. The Company projects approximately $8 million in expenditures for 2002 to expand the Verona, Missouri facility and complete a new headquarters/office lease.
- Regulatory Risks: The Company's ability to sell ethylene oxide depends on EPA re-registration, which is pending due to agency backlogs. The Verona facility was a former Superfund site; remediation is believed complete, and the Company is indemnified against prior owner liabilities.
- Customer Concentration: One customer (IBA) accounted for 11% of net sales and 11% of accounts receivable in 2001. Loss of this customer could have a material adverse effect.
- Accounting Changes: The Company adopted SFAS No. 142 effective January 1, 2002, ceasing goodwill amortization in favor of annual impairment testing. Preliminary indicators suggest no material impact, but the assessment is ongoing.
- Contingent Consideration: Up to $2.75 million in additional payment may be due to sellers based on future gross margin performance of acquired product lines.
Investor Verification Checklist
- Verify the status of the EPA re-registration for ethylene oxide and potential delays.
- Monitor the performance of the acquired Unencapsulated Feed Supplements segment to ensure it meets gross margin thresholds for contingent payments.
- Assess the impact of the 11% customer concentration risk on future revenue stability.
- Review the 2002 capital expenditure plan ($8 million) against projected cash flows and debt covenants.
- Confirm the outcome of the SFAS No. 142 goodwill impairment test expected by June 30, 2002.